Nanobiotix names board member, creates new department
This article was originally published in Clinica
Executive Summary
Nanobiotix, a clinical-stage company developing cancer therapies based on nanoparticles, has named company chief financial officer Philippe Mauberna to its executive board. Mr Mauberna joined the company in May 2013. Furthermore, the Paris, France-based firm has named Sarah Gaubert head of its newly created communication and public affairs department. Prior to joining the firm, Ms Gaubert was an advisor to the French Presidency and several ministries including the Ministry of Health.